视网膜下注射与玻璃体腔注射组织型纤溶酶原激活剂治疗黄斑下出血的疗效荟萃分析
该荟萃分析纳入7项研究共353只眼,比较玻璃体腔注射(IVI)与视网膜下注射(SRI)组织型纤溶酶原激活剂治疗黄斑下出血的疗效。结果显示两组术后1个月和6个月最佳矫正视力相似,IVI组术后3个月视力更优,最终中央视网膜厚度及完全血肿移位风险比无统计学差异。
要点
- IVI组术后3个月BCVA优于SRI组,其余时间点两组相似。
- 两组最终CRT及完全血肿移位、不良事件风险比无统计学差异。
- 纳入7项研究353只眼,随访至术后6个月。
核心结论
- IVI组术后3个月BCVA更优,两组最终访视(6个月内)BCVA恢复、CRT及完全血肿移位结果相当。
主要发现
- IVI与SRI组术后1个月和6个月BCVA相似,IVI组术后3个月BCVA更优。
- 两组最终CRT相似。
- 两组完全血肿移位、总不良事件、复发性SMH、眼压升高、术后视网膜脱离及玻璃体出血的风险比均无统计学差异。
关键数值与推荐
- BCVA以logMAR评估,CRT以μm评估,完全血肿移位以风险比(RR)评估。
临床怎么用
- 对于黄斑下出血,IVI与SRI在最终视力、CRT及血肿移位方面结果相当,IVI在术后3个月视力上可能更优。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To estimate the efficacy of intravitreal injection (IVI) versus subretinal injection (SRI) of tissue plasminogen activator in the treatment of submacular hemorrhage (SMH). METHODS: A comprehensive literature search was conducted in six major data sets from inception to 31 October 2025. Random effects meta-analysis was performed to evaluate the final best-corrected visual acuity (BCVA, logMAR) and the changes in central retinal thickness (CRT, μm), and the risk ratio of complete displacement of hemorrhage. RESULTS: A total of seven studies on 353 eyes were finally included. Best-corrected visual acuity was similar between the IVI and SRI groups at 1 month and 6 months postoperation, while better in the IVI group 3 months postoperatively. The final CRT was similar between the two groups. There were no statistical differences between the two groups in the RRs of complete displacement of hemorrhage, total adverse events, recurrent SMH, increased intraocular pressure, postoperative retinal detachment, and vitreous hemorrhages. CONCLUSION: The IVI group showed a better BCVA at 3 months, the two groups showed comparable results in the recovery of BCVA, CRT, and complete hemorrhage displacement at the final visit (within 6 months).
引用
- Zhang L, Zhang Y, Si W, et al. COMPARABLE RESULTS OF SUBRETINAL INJECTION AND INTRAVITREAL INJECTION OF TISSUE PLASMINOGEN ACTIVATOR IN THE TREATMENT OF SUBMACULAR HEMORRHAGE: A Meta-Analysis of Efficacy. Retina. 2026. PMID: 41564280. doi:10.1097/IAE.0000000000004774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。